Aptose Biosciences Terminates Material Agreement
Ticker: APTOF · Form: 8-K · Filed: May 31, 2024 · CIK: 882361
Sentiment: neutral
Topics: agreement-termination, regulatory-filing
TL;DR
Aptose Biosciences terminated a key deal, filing an 8-K on 5/31/24.
AI Summary
Aptose Biosciences Inc. filed an 8-K on May 31, 2024, reporting the termination of a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements/exhibits. The company, formerly known as Lorus Therapeutics Inc., is based in Toronto, Canada.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, financial standing, and future strategic direction.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement introduces uncertainty regarding the company's business strategy and financial future.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- May 31, 2024 (date) — Date of report
FAQ
What was the specific material definitive agreement that Aptose Biosciences Inc. terminated?
The filing does not specify the exact nature or counterparty of the terminated material definitive agreement.
When was the termination of the material definitive agreement effective?
The filing indicates the date of the earliest event reported is May 31, 2024, which is presumed to be the effective date of the termination.
Are there any financial implications disclosed regarding the termination?
The filing mentions financial statements and exhibits are included, but specific financial impacts of the termination are not detailed in the provided text.
What is the primary business of Aptose Biosciences Inc.?
Aptose Biosciences Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code.
Where is Aptose Biosciences Inc. headquartered?
Aptose Biosciences Inc. is headquartered in Toronto, Canada.
Filing Stats: 598 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-05-31 08:05:15
Key Financial Figures
- $50.0 m — regate offering sales proceeds of up to $50.0 million, through JonesTrading. The Compan
Filing Documents
- f8k_053124.htm (8-K) — 16KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-24-003181.txt ( ) — 225KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_053124_htm.xml (XML) — 3KB
02. Termination of a Material Definitive Agreement
Item 1.02. Termination of a Material Definitive Agreement. On May 30, 2024, Aptose Biosciences Inc. (the " Company ") provided notice of its termination, effective May 30, 2024, of the Equity Distribution Agreement, dated December 9, 2022 (the " Sales Agreement "), by and between the Company and JonesTrading Institutional Services LLC ("JonesTrading "). As previously reported, pursuant to the terms of the Sales Agreement, the Company could offer and sell its common shares, having aggregate offering sales proceeds of up to $50.0 million, through JonesTrading. The Company is not subject to any termination penalties related to the termination of the Sales Agreement.
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On May 31, 2024, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. 99.1 Press Release dated May 31, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: May 31, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer